Physician profile
Peter J Wong
NPI 1811971567
$4,439.59
in general payments reported to CMS, 2019-2025
37 companies · $460 in 2025
The $460 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $413 · 2020: $303 · 2021: $1,002 · 2022: $1,016 · 2023: $384 · 2024: $861 · 2025: $460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,705.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $680.75 | 2021 | |
| Sumitomo Pharma America, INC. | $384.80 | 2023-2025 | Myfembree |
| Amgen INC. | $383.77 | 2019-2025 | Evenity, Prolia |
| Abbvie INC. | $371.58 | 2019-2023 | Lo Loestrin Fe, Liletta |
| Myovant Sciences INC. | $266.23 | 2021-2022 | |
| Daiichi Sankyo INC. | $248.94 | 2020-2022 | |
| Evofem Biosciences, INC. | $220.40 | 2021-2025 | Phexxi, Solosec, Phexx |
| Organon LLC | $190.50 | 2022-2025 | Nexplanon |
| Shield Therapeutics INC | $151.71 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $148.78 | 2019-2023 | |
| Sage Therapeutics, LLC | $117.89 | 2024-2025 | Zurzuvae |
| Exeltis, USA INC. | $111.97 | 2020-2025 | Slynd |
| Coopersurgical, INC. | $103.65 | 2019-2025 | Paragard T 380a |
| Baxter Healthcare | $102.97 | 2024-2025 | Tisseel, Perclot |
| Merck Sharp & Dohme LLC | $102.58 | 2019-2025 | Gardasil 9, Gardasil |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $94.44 | 2019-2021 | |
| Pacira Pharmaceuticals Incorporated | $77.95 | 2020-2024 | Exparel |
| Amag Pharmaceuticals, INC. | $69.53 | 2019-2020 | |
| Ethicon US, LLC | $63.11 | 2024-2025 | Enseal X1, Harmonic, Enseal |
| Aspira Women'S Health INC | $56.16 | 2019-2024 | Ova1 |
| Scynexis, INC. | $49.35 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $49.06 | 2022 | |
| Pfizer INC. | $46.95 | 2023-2024 | |
| Becton, Dickinson and Company | $42.44 | 2021-2024 | Phasix Mesh |
| Astellas Pharma US INC | $34.63 | 2024 | Veozah |
| Alexion Pharmaceuticals, INC. | $34.61 | 2019 | |
| Avion Pharmaceuticals | $28.01 | 2021-2022 | |
| Medtronic, INC. | $27.80 | 2022 | |
| Abbott Laboratories | $26.87 | 2022 | |
| Hologic Sales and Service, LLC | $26.65 | 2022 | |
| Davol INC. | $23.58 | 2022 | |
| Novo Nordisk INC | $21.46 | 2025 | Wegovy |
| Roche Diagnostics Corporation | $18.62 | 2020 | |
| Arjo INC. | $17.60 | 2025 | |
| Smith+Nephew, INC. | $16.49 | 2025 | Pico 14 |
| Lupin INC. | $14.93 | 2019 | |
| Urovant Sciences INC | $12.83 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Wong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.